中文｜English
ISSN 1001-5256 (Print)
ISSN 2097-3497 (Online)
CN 22-1108/R
Volume 42 Issue 9
Sep.  2026
Turn off MathJax
Article Contents
Article Navigation >  Journal of Clinical Hepatology  > 2026  >  42(9): 2162-2170

Regulatory effect of miR-21-5p in bone marrow mesenchymal stem cell-derived exosome on angiogenesis

DOI: 10.12449/JCH260921

  • Center of Infectious Diseases and Hepatology，The First Affiliated Hospital of Xinjiang Medical University，Urumqi 830000，China

Research funding:

“Tianshan Talents” High-Level Medical and Health Talent Cultivation Program (TSYC202301B018)

More Information
  • Corresponding author: Lu Xiaobo， xjykdluxiaobo@126.com （ORCID： 0000-0001-5532-7551）; Zheng Rongjiong， zhengrongjiong@163.com （ORCID： 0000-0002-8611-6113）
  • Received Date: 2026-02-24
  • Accepted Date: 2026-05-11
  • Published Date: 2026-09-25
    Abstract
  •   Objective  To investigate the regulatory effect of miR-21-5p in bone marrow mesenchymal stem cell-derived exosome （BMSC-Exo） on angiogenesis through the phosphatidylinositol 3-kinase （PI3K）/protein kinase B （Akt） signaling pathway.  Methods  Bone marrow mesenchymal stem cells （BMSCs） were isolated from rats， cultured， and divided into negative control group （NC group） and inhibitor group， which were transfected with miR-21-5p negative control and miR-21-5p inhibitor， respectively， and then exosomes were extracted and identified. Exosomes were co-cultured with human umbilical vein endothelial cells （HUVECs）. MTT assay was used to measure cell proliferation （24， 48， and 72 hours）， tube formation assay was used to assess angiogenesis ability， and Western blot was used to measure the protein expression levels of phosphorylated Akt （p-Akt）， total Akt， and vascular endothelial growth factor （VEGF）. The change in the angiogenesis ability of HUVECs was observed after treatment with the PI3K inhibitor LY294002. The independent samples t-test was used for comparison of continuous data between two groups， and a one-way analysis of variance was used for comparison between multiple groups， while the least significant difference t-test was used for further comparison between two groups.  Results  Flow cytometry showed that the third-generation BMSCs showed high expression levels of CD29 （98.18%） and CD90 （97.85%） and a low expression level of CD45 （0.22%）. Quantitative real-time reverse transcription-polymerase chain reaction showed that compared with the NC group， there was a significant reduction in the relative expression level of miR-21-5p in BMSCs after transfection with miR-21-5p inhibitor （0.38±0.05 vs 1.00±0.08， t=11.38， P<0.01）. MTT assay showed that compared with the control group， the 25， 50， 100， and 200 μg/mL exosome treatment groups had a significant increase in the proliferative activity of HUVECs （all P<0.05）， among which 100 μg/mL exosome treatment for 72 hours showed the most significant pro-proliferative effect， while the 400 μg/mL exosome treatment group showed a significant reduction in the proliferative activity of HUVECs （P<0.01）. Tube formation assay showed that compared with the control group and the NC-Exo group， the inhibitor-Exo group showed a significant reduction in angiogenesis ability （both P<0.05）， and compared with the inhibitor-Exo group， there was a further significant reduction in angiogenesis ability after addition of the PI3K inhibitor LY294002 （P<0.01）. Western blot showed that compared with the control group and the NC-Exo group， the inhibitor-Exo group had significant reduction in the protein expression levels of p-Akt and VEGF （all P<0.05）， and compared with the inhibitor-Exo group， the protein expression levels of p-Akt and VEGF further decreased significantly after the addition of LY294002 （both P<0.01）.  Conclusion  BMSC-Exo targets and activates the PI3K/Akt signaling pathway through miR-21-5p， upregulates the expression of VEGF， and promotes vascular endothelial cell proliferation and angiogenesis.

     

    • FullText(HTML)
  • loading
    • References(39)
  • [1]
    Liver Failure and Artificial Liver Group, Chinese Society of Infectious Diseases, Chinese Medical Association; Severe Liver Disease and Artificial Liver Group, Chinese Society of Hepatology, Chinese Medical Association. Guideline for diagnosis and treatment of liver failure(2024 version)[J]. J Clin Hepatol, 2024, 40( 12): 2371- 2387. DOI: 10.12449/JCH241206.

    中华医学会感染病学分会肝衰竭与人工肝学组, 中华医学会肝病学分会重型肝病与人工肝学组. 肝衰竭诊治指南(2024年版)[J]. 临床肝胆病杂志, 2024, 40( 12): 2371- 2387. DOI: 10.12449/JCH241206.
    [2]
    Maiwall R, Kulkarni A V, Arab J P, et al. Acute liver failure[J]. Lancet, 2024, 404( 10454): 789- 802. DOI: 10.1016/S0140-6736(24)00693-7.
    [3]
    Naved S A, Ali Parpia S S. Anaesthetic management of liver transplantation in patients with fulminant hepatic failure[J]. J Pak Med Assoc, 2025, 75( 1): 111- 114. DOI: 10.47391/JPMA.9055.
    [4]
    Sorbini M, Carradori T, Patrono D, et al. Circulating cell-free DNA in liver transplantation: A pre- and post-transplant biomarker of graft dysfunction[J]. Artif Organs, 2025, 49( 4): 649- 662. DOI: 10.1111/aor.14910.
    [5]
    Khanam A, Kottilil S. Acute-on-chronic liver failure: Pathophysiological mechanisms and management[J]. Front Med, 2021, 8: 752875. DOI: 10.3389/fmed.2021.752875.
    [6]
    Sarin S K, Choudhury A, Kumar A, et al. Acute-on-chronic liver failure: Pathophysiological mechanisms and clinical management[J]. Nat Rev Gastroenterol Hepatol, 2026, 23( 5): 411- 431. DOI: 10.1038/s41575-025-01159-4.
    [7]
    Furuta T, Furuya K, Zheng Y W, et al. Novel alternative transplantation therapy for orthotopic liver transplantation in liver failure: A systematic review[J]. World J Transplant, 2020, 10( 3): 64- 78. DOI: 10.5500/wjt.v10.i3.64.
    [8]
    Psaraki A, Ntari L, Karakostas C, et al. Extracellular vesicles derived from mesenchymal stem/stromal cells: The regenerative impact in liver diseases[J]. Hepatology, 2022, 75( 6): 1590- 1603. DOI: 10.1002/hep.32129.
    [9]
    Maldonado V V, Patel N H, Smith E E, et al. Clinical utility of mesenchymal stem/stromal cells in regenerative medicine and cellular therapy[J]. J Biol Eng, 2023, 17( 1): 44. DOI: 10.1186/s13036-023-00361-9.
    [10]
    Luo Xiaofan, Luo Yehao, Ting Lyu, et al. Regulating mechanism of mesenchymal stem cells on the progression of liver cirrhosis[J]. J Liaoning Univ Tradit Chin Med, 2022, 24( 8): 65- 69. DOI: 10.13194/j.issn.1673-842x.2022.08.015.

    罗筱凡, 罗业浩, 吕挺, 等. 间充质干细胞对肝硬化进展的调控机制[J]. 辽宁中医药大学学报, 2022, 24( 8): 65- 69. DOI: 10.13194/j.issn.1673-842x.2022.08.015.
    [11]
    Mittal A, Jakhmola V R, Baweja S. Bioengineered extracellular vesicles: The path to precision medicine in liver diseases[J]. Liver Res, 2025, 9( 1): 17- 28. DOI: 10.1016/j.livres.2025.02.002.
    [12]
    Youssef E, Palmer D, Fletcher B, et al. Exosomes in precision oncology and beyond: From bench to bedside in diagnostics and therapeutics[J]. Cancers, 2025, 17( 6): 940. DOI: 10.3390/cancers17060940.
    [13]
    Wang X Q, Munson M J, Friis K, et al. Hybrid extracellular vesicles for efficient loading and functional delivery of mRNA[J]. J Extracell Vesicles, 2025, 14( 12): e70201. DOI: 10.1002/jev2.70201.
    [14]
    Mathieu M, Martin-Jaular L, Lavieu G, et al. Specificities of secretion and uptake of exosomes and other extracellular vesicles for cell-to-cell communication[J]. Nat Cell Biol, 2019, 21( 1): 9- 17. DOI: 10.1038/s41556-018-0250-9.
    [15]
    Shokravi S, Borisov V, Zaman B A, et al. Mesenchymal stromal cells(MSCs) and their exosome in acute liver failure(ALF): A comprehensive review[J]. Stem Cell Res Ther, 2022, 13( 1): 192. DOI: 10.1186/s13287-022-02825-z.
    [16]
    Wang J L, Huang D Q, Ren H Z, et al. Biomimic trained immunity-MSCs delivery microcarriers for acute liver failure regeneration[J]. Small, 2022, 18( 36): e2200858. DOI: 10.1002/smll.202200858.
    [17]
    Sun Lieqian, Gu Mengyu, Yang Jie, et al. Effect of bone marrow-derived mesenchymal stem cell transplantation on mitochondrial autophagy in rats with vascular dementia through ROS/Nrf2 signaling and its mechanism[J]. J Jilin Univ Med Ed, 2025, 51( 3): 610- 620. DOI: 10.13481/j.1671-587X.20250306.

    孙烈乾, 顾梦宇, 杨杰, 等. 骨髓来源的间充质干细胞移植通过ROS/Nrf2信号对血管性痴呆大鼠线粒体自噬的影响及其机制[J]. 吉林大学学报(医学版), 2025, 51( 3): 610- 620. DOI: 10.13481/j.1671-587X.20250306.
    [18]
    Zhang L, Song Y L, Chen L, et al. miR-20a-containing exosomes from umbilical cord mesenchymal stem cells alleviates liver ischemia/reperfusion injury[J]. J Cell Physiol, 2020, 235( 4): 3698- 3710. DOI: 10.1002/jcp.29264.
    [19]
    Kim S H, Kim C H, Lee C H, et al. Glycoengineered stem cell-derived extracellular vesicles for targeted therapy of acute kidney injury[J]. Biomaterials, 2025, 318: 123165. DOI: 10.1016/j.biomaterials.2025.123165.
    [20]
    Wang Z R, Ling J, You S L, et al. Exosomes derived from liver failure patients’ plasma stimulated mesenchymal stem cells alleviate acute liver failure[J]. Stem Cell Res Ther, 2025, 16( 1): 48. DOI: 10.1186/s13287-025-04163-2.
    [21]
    Li Rui, Wang Dianxiang, Liang Zhaowei, et al. Current research status and application prospects of mesenchymal stem cell-derived exosomes in islet transplantation[J]. Organ Transplantation, 2025, 16( 1): 163- 168. DOI: 10.12464/j.issn.1674-7445.2024194.

    李睿, 王殿相, 梁兆伟, 等. 间充质干细胞来源的外泌体在胰岛移植中的作用研究现状及应用前景[J]. 器官移植, 2025, 16( 1): 163- 168. DOI: 10.12464/j.issn.1674-7445.2024194.
    [22]
    Zheng Rongjiong, Deng Zerun, Han Dan, et al. Mechanism underlying rat hepatocyte apoptosis regulated by exosomes derived from bone marrow mesenchymal stem cells[J]. Chin J Tissue Eng Res, 2024, 28( 1): 44- 49. DOI: 10.12307/2023.916.

    郑嵘炅, 邓泽润, 韩丹, 等. 骨髓间充质干细胞来源外泌体调节大鼠肝细胞凋亡的机制[J]. 中国组织工程研究, 2024, 28( 1): 44- 49. DOI: 10.12307/2023.916.
    [23]
    Maher S Z, Schreibman I R. The clinical spectrum and manifestations of acute liver failure[J]. Clin Liver Dis, 2018, 22( 2): 361- 374. DOI: 10.1016/j.cld.2018.01.012.
    [24]
    Wang Y J, Xie X L, Liu H Q, et al. LR12 promotes liver repair by improving the resolution of inflammation and liver regeneration in mice with thioacetamide-(TAA-) induced acute liver failure[J]. Mediators Inflamm, 2021, 2021: 2327721. DOI: 10.1155/2021/2327721.
    [25]
    Li M J, Wang Z F, Yan X X, et al. Luopan mountain pig bone marrow mesenchymal stem cells promote liver regeneration in D-galactosamine-induced acute liver failure rats by regulating the PTEN-PI3K/Akt/mTOR pathway[J]. Biology, 2025, 14( 10): 1363. DOI: 10.3390/biology14101363.
    [26]
    Stravitz R T, Fontana R J, Karvellas C, et al. Future directions in acute liver failure[J]. Hepatology, 2023, 78( 4): 1266- 1289. DOI: 10.1097/HEP.0000000000000458.
    [27]
    Luo S, Wu F, Yang X J. Single-cell transcriptome atlas reveals mitophagy dynamics in acute chemical injury model and the role of MSCs transplantation[J]. Stem Cell Res Ther, 2025, 16( 1): 350. DOI: 10.1186/s13287-025-04491-3.
    [28]
    Xie D, Yu L N, Wang Z Y, et al. Exosomes derived from human umbilical cord mesenchymal stem cells inhibit hepatocyte pyroptosis via miR-423-5p/ZBP1 in acute liver failure[J]. Hum Cell, 2025, 38( 5): 124. DOI: 10.1007/s13577-025-01248-1.
    [29]
    Tang H X, Lu W, Yang Q, et al. Exosomes derived from 3D-cultured hUCMSCs exhibit superior hepatoprotection against ALF[J]. iScience, 2025, 28( 9): 113419. DOI: 10.1016/j.isci.2025.113419.
    [30]
    Wu J, Chen L H, Sun S Y, et al. Mesenchymal stem cell-derived exosomes: The dawn of diabetic wound healing[J]. World J Diabetes, 2022, 13( 12): 1066- 1095. DOI: 10.4239/wjd.v13.i12.1066.
    [31]
    Vadhan A, Gupta T, Hsu W L. Mesenchymal stem cell-derived exosomes as a treatment option for osteoarthritis[J]. Int J Mol Sci, 2024, 25( 17): 9149. DOI: 10.3390/ijms25179149.
    [32]
    Yao Shun, Yang Yongqi, Liu Cuicui, et al. Advances in the druggability and clinical translation of platelets[J]. Chin J Cell Biol, 2026, 48( 1): 116- 128. DOI: 10.11844/cjcb.2026.01.0008.

    姚舜, 杨咏琪, 刘翠翠, 等. 血小板临床转化研究进展[J]. 中国细胞生物学学报, 2026, 48( 1): 116- 128. DOI: 10.11844/cjcb.2026.01.0008.
    [33]
    Su Qiumei, Zhou Ou, Tan Wen, et al. Progress of mechanism of mesenchymal stem cell-derived extracellular vesicles in the treatment of bronchopulmonary dysplasia[J]. J Pediatr Pharm, 2026, 32( 1): 52- 56. DOI: 10.13407/j.cnki.jpp.1672-108X.2026.01.014.

    粟秋梅, 周欧, 谭雯, 等. 间充质干细胞来源的细胞外囊泡治疗支气管肺发育不良机制研究进展[J]. 儿科药学杂志, 2026, 32( 1): 52- 56. DOI: 10.13407/j.cnki.jpp.1672-108X.2026.01.014.
    [34]
    He L L, Zhang H W, Zhao N B, et al. A novel approach in biomedical engineering: The use of polyvinyl alcohol hydrogel encapsulating human umbilical cord mesenchymal stem cell-derived exosomes for enhanced osteogenic differentiation and angiogenesis in bone regeneration[J]. Int J Biol Macromol, 2024, 270: 132116. DOI: 10.1016/j.ijbiomac.2024.132116.
    [35]
    Tan W, Ma L, Li Y L, et al. Glycoside components promote endothelial progenitor cell-derived exosomes repairing damaged vascular endothelium via the PI3K/AKT signaling pathway[J]. Phytomedicine, 2025, 141: 156694. DOI: 10.1016/j.phymed.2025.156694.
    [36]
    He P P, Zeng W R, Li J, et al. ATF4 regulates PI3K/AKT signaling axis to promote angiogenesis after myocardial infarction[J]. Vitro Cell Dev Biol Anim, 2025, 61( 8): 909- 920. DOI: 10.1007/s11626-025-01085-4.
    [37]
    Peng C H, Chen H M, Li Y W, et al. LRIG3 suppresses angiogenesis by regulating the PI3K/AKT/VEGFA signaling pathway in glioma[J]. Front Oncol, 2021, 11: 621154. DOI: 10.3389/fonc.2021.621154.
    [38]
    Li J, Shi R D, Li Q, et al. miRNA-21-5p targeting PTEN to regulate PI3K/Akt/mTOR pathway in retinal pigment epithelial cell photodamage[J]. Int J Ophthalmol, 2025, 18( 4): 575- 581. DOI: 10.18240/ijo.2025.04.02.
    [39]
    Cheng Y, Guo Q Y, Cheng Y L, et al. Endostatin-expressing endometrial mesenchymal stem cells inhibit angiogenesis in endometriosis through the miRNA-21-5p/TIMP3/PI3K/Akt/mTOR pathway[J]. Stem Cells Transl Med, 2025, 14( 2): szae079. DOI: 10.1093/stcltm/szae079.
    • Relative Articles
    • Supplements(0)
    • Cited By
  • 加载中

Catalog

    通讯作者: 陈斌, bchen63@163.com
    • 1. 

      沈阳化工大学材料科学与工程学院 沈阳 110142

    1. 本站搜索
    2. 百度学术搜索
    3. 万方数据库搜索
    4. CNKI搜索

    Figures(9)

    Get Citation
    PDF
    XML

    Article Metrics

    Article views (94) PDF downloads(12) Cited by()
    Proportional views
    Related
        

    The first journal specializing in hepatobiliary and pancreatic diseases in China

    Supervisor：Ministry of Education of the People's Republic of China

    Sponsor：Jilin University

    Academic Support: Chinese Society of Hepatology，Chinese Medical Association

    Address: 461 Xinjiang Road, Changchun

    Submit：0431-88782044

    Peer review：0431-88783542

    Email：lcgdb@vip.163.com

    About Journal

    Submission Guideline

    Journal Online

    Hepatobiliary College

    Guidelines

    YesterdayIP[]YesterdayPV[]TodayIP[]TodayPV[]Online[]

    Website Design © 2020 Editorial Board of Journal of Clinical Hepatology 吉ICP备10000617号-1 Supported by: Beijing Renhe Information Technology Co. Ltd  

    /

    DownLoad:  Full-Size Img  PowerPoint
    Return
    Return